breast procedure
Recently Published Documents


TOTAL DOCUMENTS

4
(FIVE YEARS 1)

H-INDEX

2
(FIVE YEARS 0)

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12525-e12525
Author(s):  
Elizabeth R. Berger ◽  
Srinivasa Sevilimedu Veeravalli ◽  
Monica Morrow ◽  
Alexandra S. Heerdt

e12525 Background: Optimal approach to early-stage breast cancer (BC) management in women ≥70y is unclear. Studies have demonstrated improved local control but no survival advantage with use of radiation therapy (RT) after breast-conservation therapy (BCT). The impact on survival of other management decisions, including breast procedure, axillary staging (AS), systemic treatment, and patient comorbidities is unknown. We evaluate the effect of each treatment decision on overall survival (OS), disease-free survival (DFS), and breast-cancer specific survival (BCSS). Methods: Patients age ≥70y with cT1N0/ER+/HER2- tumors undergoing surgery from 2011-2013 were identified from a prospectively maintained, single-institution database. Clinicopathologic features were evaluated. 10-year estimated mortality from comorbidity was calculated using a Suemoto index (SI). Univariate and multivariable associations were assessed using Cox modeling. Kaplan-Meier method was used to estimate OS and DFS. Results: 338 patients were identified: 312 (92%) underwent BCT; 26 (8%) had mastectomy. Median age was 75.5y (70-101); median tumor size was 1.0cm (0.1-1.9); median SI was 42.5(22-99). With a median follow-up of 60 mos, 25 patients died—1 from BC, for an OS rate of 92.8% and BCSS of 99.7%. 9 patients developed a locoregional recurrence and 1 developed distant recurrence, representing a 5-year DFS rate of 97.8%. There were no differences in DFS by age groups (≤75, 76-80, > 80; p = 0.1). On univariate analysis, DFS did not vary by age, breast procedure, or receipt of chemotherapy. It was improved in those who had AS and a lower SI (p < 0.01). OS was better in those patients who had AS, had recurrence score performed and had radiation therapy, reflecting lower SI. On multivariable analysis, lack of AS (HR 10.5, p < 0.01) and higher SI (HR 1.03, p < 0.01) were the only variables associated with worse OS. Lack of AS became non-significant in those > 80y. No treatment decision led to improved BCSS. When comparing patients with local or systemic recurrence vs those without recurrence, there was no difference in OS (p = 0.4) or BCSS (p = NS). Conclusions: Decisions in early-stage BC in the elderly are complex due to competing morbidities. While DFS and OS may vary based on treatment variables, no specific care component affected BCSS. Treatment discussions in elderly BC patients should emphasize the risks/benefits of each care component, taking into consideration the patient’s comorbidities and allowing for the patient’s understanding of outcomes and quality of life.


2011 ◽  
Vol 77 (5) ◽  
pp. 640-646 ◽  
Author(s):  
Marcia E. Bouton ◽  
Krista L. Wilhelmson ◽  
Ian K. Komenaka

Wire guided breast procedures are the most commonly used breast conserving operation for nonpalpable cancers. We did a retrospective review of all patients who underwent the wire guided breast procedure at a county hospital with an associated surgical residency program. Twenty-eight patients underwent the procedure with intraoperative ultrasound from June 2009 to March 2010. Breast cancer patients who underwent a wire-guided lumpectomy with intraoperative ultrasound had a lower rate of positive margins (9% vs 26%, P = 0.28) and a smaller volume of tissue removed (126 cm3 vs 146 cm3, P = 0.57). For wire guided excisional biopsy, the volume of tissue removed was smaller in the intraoperative ultrasound group (30 cm3 vs 44 cm3, P = 0.17) and the targeted area was more likely to be removed in one specimen (1.1 vs 1.5, P = 0.03). Intraoperative ultrasound can improve surgical outcomes of the wire guided breast procedure.


2002 ◽  
Vol 9 (3) ◽  
pp. 272-277 ◽  
Author(s):  
Sandra L. Wong ◽  
Michael J. Edwards ◽  
Celia Chao ◽  
Todd M. Tuttle ◽  
R. Dirk Noyes ◽  
...  

1988 ◽  
Vol 5 (2) ◽  
pp. 81-82
Author(s):  
Melvin A. Shiffman

The cosmetic surgeon should be aware of the natural history of breast cancer, the method for diagnosis, and alternatives of treatment. Diagnosis can be made prior to or during a cosmetic breast procedure, usually at a time when the neoplasm is highly curable.


Sign in / Sign up

Export Citation Format

Share Document